ALT Jan 2026 12.000 call
| Previous close | 3.8000 |
| Open | 3.8000 |
| Bid | 1.6000 |
| Ask | 2.5500 |
| Strike | 12.00 |
| Expiry date | 2026-01-16 |
| Day's range | 3.8000 - 3.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 40 |
GlobeNewswireAltimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with MASH biopsy readouts in Q1 2025 Based on a quantitative systems pharmacology (QSP) computational model, pemvidutide’s GLP-1/glucagon dual agonism could have additive effects on MASH resolution and fibrosis improvement compared with GLP-1 alone Lipidomic profiling reinforces the disease modifying potentia
- GlobeNewswire
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20
- GlobeNewswire
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) will be presented at the EASL International Liver Congress™ 2024 in Milan, Italy. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for
